Page last updated: 2024-11-10

prostaglandin b2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin B2: RN given refers to (5Z,13E,15S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280881
CHEMBL ID1901620
CHEBI ID28099
SCHEMBL ID3368055
MeSH IDM0124369

Synonyms (49)

Synonym
(5z,13e,15s)-15-hydroxy-9-oxoprosta-5,8(12),13-trien-1-oic acid
CHEBI:28099 ,
BRD-K82865713-001-02-6
15s-hydroxy-9-oxo-5z,8(12),13e-prostatrienoic acid
LMFA03010018
BCBCMAP01_000173
BSPBIO_001484
IDI1_033954
pgb2
13367-85-6
C05954
prostaglandin b2
prostaglandin b2, >=98%, synthetic
DB02304
NCGC00161283-02
NCGC00161283-01
NCGC00161283-03
HMS1989K06
BML1-F04
HMS1791K06
HMS1361K06
SCHEMBL3368055
(z)-7-[2-[(e,3r)-3-hydroxyoct-1-enyl]-5-oxocyclopenten-1-yl]hept-5-enoic acid
(z)-7-[2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopenten-1-yl]hept-5-enoic acid
prosta-5,8(12),13-trien-1-oicacid, 15-hydroxy-9-oxo-, (5z,13e,15s)-
prosta-5,8(12),13-trien-1-oic acid, 15-hydroxy-9-oxo-, (5z,13e,15s)-
unii-biu61o9t9t
biu61o9t9t ,
15-hydroxy-9-oxoprosta-5,8(12),13-trienoic acid
dinoprostone impurity e [ep impurity]
(z)-7-(2-((e)-(3s)-3-hydroxyoct-1-enyl)-5-oxocyclopent-1-enyl)hept-5-enoic acid
15.alpha.-hydroxy-9-ketoprosta-5,8(12),13-trienoic acid
dinoprostone impurity, (5z,13e,15s)-15-hydroxy-9-oxoprosta-5, 8(12),13-trien-1-oic acid- [usp impurity]
(5z,13e,15s)-15-hydroxy-9-oxoprosta-5, 8(12),13-trien-1-oic acid
PRFXRIUZNKLRHM-HKVRTXJWSA-N
CHEMBL1901620
HMS3648K17
HMS3402K06
pgb2 (prostaglandin b2)
J-006426
pgb2-[d4]
prosta-glandinb2
Q27093323
sr-01000946234
SR-01000946234-1
DTXSID50864391
HY-113042
CS-0059421
AKOS040755329
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins B
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Eicosanoid metabolism via cyclooxygenases (COX)137
Arachidonic acid (AA, ARA) oxylipin metabolism076
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.84370.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (30.00)18.7374
1990's14 (46.67)18.2507
2000's4 (13.33)29.6817
2010's3 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.28 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]